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Abstract
Introduction
Type 1 diabetes (T1DM) patients are at increased risk of coronary artery disease (CAD).
This pilot study sought to evaluate the relationship between epicardial adipose tissue (EAT)
and intra-thoracic adipose tissue (IAT) volumes and cardio-metabolic risk factors in T1DM.
Method
EAT/IAT volumes in 100 patients, underwent non-contrast cardiac computed tomography in
the Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) study were measured by a certified reader. Fat was defined
as pixels’ density of -30 to -190 Hounsfield Unit. The associations were assessed using–
Pearson partial correlation and linear regression models adjusted for gender and age with
inverse probability sample weighting.
Results
The weighted mean age was 43 years (range 32–57) and 53% were male. Adjusted for gen-
der, Pearson correlation analysis showed a significant correlation between age and EAT/
IAT volumes (both p<0.001). After adjusting for gender and age, participants with greater
BMI, higher waist to hip ratio (WTH), higher weighted HbA1c, elevated triglyceride level,
and a history of albumin excretion rate of equal or greater than 300 mg/d (AER300) or end
stage renal disease (ESRD) had significantly larger EAT/IAT volumes.
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Conclusion
T1DM patients with greater BMI, WTH ratio, weighted HbA1c level, triglyceride level and
AER300/ESRD had significantly larger EAT/IAT volumes. Larger sample size studies are
recommended to evaluate independency.
Introduction
Several large studies have shown a high prevalence of cardiovascular disease (CVD) among
participants with type 1 diabetes (T1DM). [1–3]While the incident of CVD in 35–44 years old
age non-diabetic population has been reported as 0.1%, the Pittsburgh Epidemiology of Diabe-
tes Complications (EDC) study reported 0.98% per year incidence of major coronary artery
disease (CAD) events, among 28–38 years with T1DM.[4] Moreover, a minimum 10-fold
increase in mortality due to cardiovascular disease among T1DM patients was reported.[5]
Furthermore, there is an independent association between CAD events and major coronary
artery disease risk factor including lipid profile, hypertension, smoking, and nephropathy and
markers of inflammation among patients with T1DM. [4,6–8]
Adipose tissue, as the biggest endocrine organ in the body, is involved with the production
of many bioactive molecules. Visceral adipose tissue and its adipose-tissue resident macro-
phages produce pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-alpha) and
interleukin-6 (IL-6). These adipose tissue inflammation mediators may promote endothelial
dysfunction as well as development and progression of atherosclerosis. Nevertheless, the role
of other adipose tissue depot, such as epicardial adipose tissue (EAT) and intra-thoracic adi-
pose tissue (IAT), play in the development of CAD has not been established. This pilot study
sought to examine the relation between EAT and IAT volumes with selected cardio-metabolic
risk factors, treatment method, and glycemic levels among T1DM patients.
Study Design and Method
Ethics statement
All human research was approved by the relevant institutional review boards, and conducted
according to the Declaration of Helsinki. Institutional Review Board (IRB) approval was
obtained by each of the individual clinical centers (Albert Einstein College of Medicine, Case
Western Reserve University, Weill Cornell Medical College, Henry Ford Health System, Inter-
national Diabetes Center, Joslin Diabetes Center, Massachusetts General Hospital, Mayo Foun-
dation, Medical University of South Carolina, Northwestern University, University of
California, San Diego, University of Iowa, University of Maryland School of Medicine, Univer-
sity of Michigan, University of Minnesota, University of Missouri, University of Pennsylvania,
University of Pittsburgh, University of South Florida, University of Tennessee, University of
Texas Southwestern Medical Center at Dallas, University of Toronto, University of Washing-
ton, University of Western Ontario, Vanderbilt University, Washington University, St. Louis,
Yale University School of Medicine), Computed Tomography Reading Center (Harbor UCLA
Research and Education Institute), and the Data Coordinating Center (the George Washington
University Biostatistics Center). Written informed consent was provided by each of the study
participants at the clinical centers. Consent for minor participants at study screening and ran-
domization was provided by the minor’s parent or legal guardian, as directed by local institu-
tional guidelines.
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present), Bethesda, Maryland, USA.
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Study population
This pilot study employed 100 selected participants who participated in the computed tomog-
raphy (CT) protocol in the Diabetes Control and Complications Trial /Epidemiology of Diabe-
tes Interventions and Complications (DCCT/EDIC) study. The details of the CT protocol have
been previously described [9]. The 100 patients were obtained from a case-control sample of
subjects who participated in a cardiac magnetic resonance imaging (cMRI) study and we had
access on their non-contrast cardiac CT images. The minimal dataset containing EAT and IAT
and selected covariates was available in the Supporting Information file “S1 File”.
The EDIC study[10] began in 1994 and is an ongoing, prospective observational follow-up
of the DCCT cohort[11], which was a controlled clinical trial of intensive versus conventional
diabetes treatment in 1441 subjects with type 1 diabetes. Based on the treatment protocols,
patients were randomized into two groups of intensive and conventional treatment groups.
The intensive treatment was designed to maintain glucose levels as close to the normal range as
possible utilizing three or more daily insulin injections or an insulin infusion pump, with dose
adjustments guided by frequent self-monitoring of blood glucose. Conventional treatment con-
sisted of 1–2 daily insulin injections with no specific target level[12].
Assessment of Covariates
During DCCT, participants had an annual medical history and physical examination, and lab-
oratory testing for fasting lipid levels, urinary albumin excretion rate (AER) and other risk fac-
tors for cardiovascular disease[11]. Glycated hemoglobin values (HbA1c) were measured
quarterly during DCCT[13]. During EDIC, annual medical histories were obtained, physical
exams performed and HbA1c levels were measured. Lipid profiles and urinary AER were mea-
sured in alternate years [10]. Due to the differences in the intervals between visits during
DCCT and EDIC, weighted mean HbA1c was computed with weights proportional to the time
interval between values.
Measurements of Adipose Tissue
All adipose tissue measurements were performed on the axial slices of non-contrast cardiac CT
using GE Advantage Windows 4.6 Workstations “Fig 1“. EAT was defined as the adipose tissue
between the surface of the heart and the visceral pericardium. EAT measurements were per-
formed on axial images starting from 10mm above the superior extent of the left main ostium
to the lower most slice containing a part of pericardial sac. The reader defined the boundary of
the EAT by manually tracing the pericardium. IAT measurement was performed utilizing the
same superior boundary as described above. The diaphragm defined the inferior boundary for
IAT. The anterior border of the volume was defined by the chest wall and posterior border by
the aorta, bronchi and esophagus. Adipose tissue present in the posterior mediastinum and
para-aortic adipose tissue was not included in the IAT measurements. The observer had inter-
active access to the coronal and sagittal images as an assist for accurate measurements. Adipose
tissue was discerned from the remainders with a threshold of -190 to -30 Hounsfield units.
This method provides a high repeatability, and reproducibility rate.[14] One well-trained and
certified cardiac CT reader, blinded to the patient characteristics, and other data, did all adipose
tissue measurements.
Statistical Analysis
The outcomes of this study are epicardial and intra thoracic adipose tissue volumes (EAT and
IAT). Clinical characteristics (predictors) were evaluated from the last available visit prior to or
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concurrent with the cardiac CT. The predictors are attained age, gender, attained T1DM dura-
tion, BMI, waist to hip ratio, total daily insulin dose, systolic and diastolic blood pressures, tri-
glyceride level, high density lipoprotein (HDL) level, estimated glomerular filtration rate
(eGFR), macroalbuminuria (albumin excretion rate (AER) equal or greater than 300 or end
stage renal disease (ESRD) at any time, and weighted mean HbA1c.
All analyses were weighted using the inverse of the probability of selection in the sample of
100 out of the full cohort of 1205 subjects with CT scans during EDIC so as to yield unbiased
estimates. [14, 15] The sampling probabilities were calculated for each subject in the pilot
study based on gender and tertiles of age, six strata total. The Pearson correlation coefficients
adjusting for gender were performed to assess the correlation between EAT/IAT and individual
risk factors. In addition, the association of each covariate separately was assessed using a mini-
mally adjusted model (adjusted for age and gender). After the inverse probability sample
weight adjustment, the sample cohort of 100 shared the similar summary statistics for clinical
characteristics with the full cohort (53% males, mean age 43 years, and mean HbA1c 8.1%)
“Table 1”.
All analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC). P
values<0.05 were considered statistically significant.
Results
Of the 100 patients, weighted mean aged 43 years (range 32–57), 53% were male “Table 1“. The
mean EAT and IAT volumes were significantly different in women and men; 34±15 and 41±19
in women and 43±20 and 60±33 mm3 in men, respectively (p = 0.016 and p = 0.0003) “Fig 2“.
Furthermore, EAT and IAT volumes were shown to correlate with age (r = 0.35 and 0.27,
respectively; p = 0.0018 and 0.014). No significant differences in volumes of EAT and IAT were
noted based on original DCCT treatment groups, smoking, insulin dose or duration of T1DM.
Weighted mean HbA1c during DCCT/EDIC had a significant positive correlation with both
EAT and IAT volumes after adjusting for gender. After adjusting for age and gender, the analy-
ses showed significant associations between EAT and IAT volumes and BMI, waist to hip ratio,
triglycerides, weighted mean HbA1c, and AER300/ ESRD (ever) “Table 2“. No association
was noted between EAT and IAT and HDL cholesterol, smoking, systolic, or diastolic blood
pressures. No any interaction between each covariate and sex was significant in epicardial fat
volume. Only one interaction between AER> = 300/ESRD and sex reached the significance
Fig 1. Pericardial Tracing to Define Epicardial Fat Volume.
doi:10.1371/journal.pone.0159958.g001
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level (p = 0.0093) in intrathoracic fat volume. Males patients who had AER> = 300/ESRD had
the highest intrathoracic fat volume (88 mm3; N = 6) while females patients who had AER> =
300/ESRD had the lowest intrathoracic fat volume(36 mm3; N = 2). The most significant risk
factors, waist, weighted mean HbA1c and triglycerides were adjusted in the multivariate model
besides age and gender. Weighted mean HbA1c and triglycerides were no longer significant in
the multivariate model while the waist remained significant (data not shown). In addition,
while 31% of 1205 patients in full cohort had no coronary artery calcium deposit, 28% of our
sample population showed zero coronary artery calcium score. After adjusting for gender and
sample weight, both partial correlation coefficient and p-value between coronary artery cal-
cium and EAT and IAT volumes was the same, 0.18 and 0.08, respectively. In addition, major-
ity of subjects with type 1 diabetes in the full cohort were northern European ancestry (i.e.
Caucasian), characteristics of type 1 diabetes. The fraction of other races in full cohort and
sample were 3.3% and 3.0%, respectively.
Discussion
Not only has the volume of the fat, but also the body fat distribution associated with CAD.
BMI and waist to hip ratio have been used frequently to assess the impact of the obesity on cor-
onary artery disease. However, there are many studies pointing to the possibility that use of
BMI may be responsible for the observed obesity paradox. Obesity paradox is a term indicating
high BMI may be protective and associated with greater survival in certain populations.[15,16]
Table 1. Similar Clinical Characteristics for Weighted Sample and the Full Cohort.
Weighted Sample* Full Cohort
Variable# Mean S.D. Mean S.D.
N 100 1205
Female (%) 47.5 47.5
Attained Age (years) 43 6 43 7
Intensive Treatment (%) 55.2 49.5
Insulin Dose (Units/kg/day) ‡ 0.67 0.27 0.68 0.23
Attained Duration of IDDM (years)† 22.2 4.9 21.0 4.9
Mean Glycosylated hemoglobin during DCCT/EDIC (%) 8.1 0.9 8.1 1.1
Body Mass Index (kg/m2)‡ 27.2 4.2 27.5 4.4
Waist/Hip Ratio‡ 0.85 0.07 0.85 0.09
HDL Cholesterol (mg/dl)‡ 54 12 56 15
LDL Cholesterol (mg/dl) ‡ 110 27 111 29
Triglyceride (mg/dl)‡ 80 40 90 62
AER300 or ESRD (%)‡ 9.2 8.5
eGFR‡ 106 14 103 16
Anti-hypertensive (yes)(%) 30.7 33.6
Lipid lowering medication (yes)(%) 30.1 22.2
Epicardial Fat Volume (mm3) 38.5 16.6 N/A N/A
Intrathoracic Fat Volume (mm3) 50.8 25.3 N/A N/A
# At time of CT scan in 60 (60%) of subjects or at a prior visit in 40(40%) conducted within 20 months
(average 4 months) before or after the CT scan.
N/A Not Applicable
* Adjusting for the inverse probability sample weight.
† At time of CT scan or prior visit.
‡ Measured at the last available visit prior to or at cardiac CT.
doi:10.1371/journal.pone.0159958.t001
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A recent published results of a Canadian cohort study over 54420 aged 40 or above partici-
pants, suggested that BMI acts as a misleading factor. In this study, adults with higher BMI sur-
vived more than their counterpart. But, DXA-derived body fat percentage revealed participants
with higher fat percentage had worse outcomes.[17] In contrast, visceral adipose tissue and
Fig 2. Epicardial/Intrathoracic Fat Volume with SampleWeight Adjustment by Gender. The box whisker plot
displays min and max (lower and upper whiskers), first (Q1) and third (Q3) quartile (central rectangle), median (the
segment inside the rectangle), and mean (/+ inside the rectangle).
doi:10.1371/journal.pone.0159958.g002
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more specifically EAT and IAT showed a stronger association with cardiovascular health and
events. [18–20] While, based on the current guidelines, a non-contrast cardiac CT and evalua-
tion of coronary artery calcium score is recommended for screening of CAD among diabetic
patients, it is possible to take the advantage of having EAT and IAT volumes to assess the risk
of the future events. A study in 998 apparently healthy individuals, who were randomly
selected from 6814 Multi-Ethnic Study of Atherosclerosis (MESA) participants revealed that
deposit of fat around the heart strongly predicts incident coronary artery disease, independent
of the BMI and major CAD risk factors.[21] Noteworthy, in contrast to many previous studies,
a multi-centric study was not able to find any association between epicardial fat and the pres-
ence and extent of CAC by CT, presence of obstructive CAD by cardiac catheterization, or
myocardial perfusion abnormalities by SPECT. [22] However, different from most of the other
studies and the standards that was defined earlier, a range of -45 to -195 HU was used to define
the fat. Based on the detailed studies, current standards recommended -30 to -190 HU for fat
measurement.[23,24] It means they did not considered any mass between -30 to -45 as fat.
Since this usually includes a significant mass inside the pericardium, it is possible that the dif-
ference made the results very different from the other studies. We have considered a range of
-30 to -190 HU for fat.
Table 2. Pearson Correlation* andMinimally Adjusted Model@: Epicardial Fat Volume and Intrathoracic Fat Volume Associated with Selected
Covariates.
Covariate prior to or at CT scan Epicardial Fat Volume (mm3) Intrathoracic Fat Volume (mm3)
Correlation Model Correlation Model
coefficient p-value Estimate±SE p-value coefficient p-value Estimate±SE p-value
Gender† (males vs. females) - 9.2 ± 3.7 0.0159 - 19.3 ± 5.2 0.0003
Age‡ (years) 0.35 0.0005 0.93 ± 0.29 0.0018 0.27 0.0069 1.1 ± 0.4 0.0140
Duration‡ (years) -0.18 0.0804 -0.5 ± 0.4 0.1799 -0.18 0.0680 -0.8 ± 0.5 0.1344
Treatment(Conventional vs. Intensive) N/A N/A -4.0 ± 3.3 0.2384 N/A N/A -4.6 ± 5.1 0.3696
Smoking (yes vs. no) N/A N/A 8.1 ± 4.9 0.1040 N/A N/A 9.8 ± 7.0 0.1627
BMI (kg/m2) 0.39 < 0.0001 1.6 ± 0.4 <0.0001 0.40 <0.0001 2.4 ± 0.6 <0.0001
Waist (cm) 0.50 < 0.0001 0.80 ± 0.14 < 0.0001 0.50 < 0.0001 1.17 ± 0.20 < 0.0001
Waist/Hip Ratio$ 0.58 < 0.0001 15.4 ± 2.4 < 0.0001 0.60 < 0.0001 23.8 ± 4.0 < 0.0001
Weighted HbA1C during DCCT/EDIC (%) 0.22 0.0271 4.4 ± 1.6 0.0075 0.18 0.0721 5.2 ± 2.2 0.0196
Insulin dose (units/kg/day) 0.04 0.6991 9.5 ± 5.7 0.0982 0.03 0.7847 10.6 ± 8.3 0.2075
Systolic blood pressure (mm Hg) 0.07 0.5057 0.11 ± 0.16 0.4803 0.07 0.4645 0.17 ± 0.23 0.4501
Lipid-HDL Cholesterol (mg/dl) -0.21 0.0335 -0.33 ± 0.19 0.0795 -0.21 0.0403 -0.46 ± 0.28 0.1020
Lipid-LDL Cholesterol (mg/dl) 0.08 0.4358 -0.01 ± 0.07 0.8672 -0.07 0.4639 -0.02 ± 0.10 0.8125
Triglycerides (mg/dl) 0.21 0.0330 0.09 ± 0.04 0.0273 0.20 0.0475 0.13 ± 0.07 0.0579
eGFR -0.23 0.0231 -0.08 ± 0.09 0.4113 -0.16 0.1117 -0.05 ± 0.13 0.7138
AER300 or ESRD (ever) N/A N/A 10.3 ± 5.1 0.0450 N/A N/A 20.5 ± 9.5 0.0338
Anti-hypertensive (yes vs. no) N/A N/A 3.6 ± 3.6 0.3210 N/A N/A 7.5 ± 5.4 0.1676
Lipid lowering medication (yes vs. no) N/A N/A 9.0 ± 4.0 0.0282 N/A N/A 11.3 ± 6.2 0.0696
N/A Pearson correlation was Not Applicable for binary variables.
* Pearson partial correlation was adjusted for gender and corrected with sample weight.
@ All models were adjusted for gender and age and corrected with sample weight unless otherwise indicated. A separate model was computed for each
covariate.
† Model included gender only.
‡ Model was adjusted for gender.
$ Every 0.1 unit change of waist/hip ratio in the minimally adjusted model.
doi:10.1371/journal.pone.0159958.t002
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Previous studies showed significant differences between men and women in both the fat
metabolism and pattern of fat distribution. Usually, women have a greater body fat proportion
than men. Also, subcutaneous fat storage is greater in female than male, while visceral fat
deposits are more prominent in men [25]. Our pilot study showed male gender had a strong
association with greater volumes of EAT and IAT. Also, it showed among T1DM, independent
of age, males have greater EAT and IAT volumes than females. The difference in the pattern of
fat distribution will help to detect patients with greater risk of cardiovascular disease.
Obesity and greater body fat volume have been considered one of the primary adverse
effects of insulin therapy in both Type 1 and 2 diabetes.[26,27] In the Diabetes Control and
Complications Trial, whereas waist to hip ratios did not differ, T1DM patients receiving inten-
sive insulin therapy significantly gained body weight compare to patients receiving conven-
tional therapy. Our study shows no association between total daily insulin dose and EAT or
IAT fat volumes. Likewise, neither the DCCT treatment assignment (intensive vs. conven-
tional) nor the duration of T1DM showed a relation with EAT or IAT volumes. However,
interestingly, weighted HbA1C during DCCT/EDIC showed to have a positive association with
these visceral fat volumes.
Limitations
We were not able to evaluate the independent association of EAT and IAT volumes with more
CVD risk factors due to the small sample size.
Conclusion
Among T1DM patients, accumulation of adipose tissue in epicardial and intra-thoracic spaces
were highly associated with greater BMI, bigger waist to hip ratio, greater weighted HbA1c, ele-
vated triglyceride level and a history of AER300 or ESRD). Male individuals with T1DM had
significantly larger volumes of EAT and IAT. Further studies with larger size and considering
hard events is advised.
Supporting Information
S1 File. Minimal data set with EAT and IAT and selected covariates.
(PDF)
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